Ramesh laboratory has been investigating the pathophysiology of Neurofibromatosis 2 (NF2) and Tuberous Sclerosis Complex (TSC) for almost two decades. Her lab employs molecular, genetic, cell signaling and biochemistry techniques in disease-relevant human cells to discover pathways and mechanisms of pathophysiology in NF2 and TSC. The work on NF2 in human arachnoidal and meningioma cells discovered that NF2 protein merlin is a novel negative regulator of mTORC1 signaling. This work has been translated into clinical trials with RAD001 for NF2 and sporadic meningiomas. Ramesh lab has also established CRISPR-Cas genome editing technology in human arachanoidal cells, Schwann cells and iPSCs and has used this technique to create/correct mutations in NF1, NF2, TSC1 and TSC2 generating isogenic sets of human lines for drug screening and other research efforts.